McKesson (MCK) News Today

McKesson Corporation (NYSE: MCK) shares increased as investors responded to an extended pharmaceutical distribution partnership with CVS Health and confirmation of the company’s earnings outlook.

• Positive Sentiment: CVS partnership extended through June 2032: McKesson reached an agreement to continue distributing pharmaceuticals for CVS’s mail-order, specialty and retail pharmacies, as well as distribution centers. The multiyear extension provides greater revenue visibility and reinforces a strategically important customer relationship. McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
• Positive Sentiment: Fiscal 2027 guidance reaffirmed: McKesson maintained adjusted EPS guidance of $44.20 to $45.00, broadly consistent with the $44.65 analyst consensus. The lack of a guidance reduction helped support investor confidence in operating momentum. McKesson Extends CVS Health Pact to 2032
• Positive Sentiment: Strong recent results and growth initiatives: Investors may also be carrying forward confidence from McKesson’s latest quarter, which included $105.4 billion in revenue and adjusted EPS of $9.93, up 20% year over year. The planned $2.25 billion acquisition of Precision Medicine Group further expands the company’s oncology and clinical research capabilities.
• Neutral Sentiment: Industry backdrop remains constructive: McKesson was included among medical and dental supply stocks viewed as having potential as industry prospects improve. The company is scheduled to report fiscal second-quarter results after the market close on November 4, creating a possible near-term catalyst.
• Negative Sentiment: Insider selling is a risk signal: Reported insider activity over the past six months consisted of 11 sales and no open-market purchases, including sales by CEO Brian Tyler. This may temper enthusiasm, although the transactions did not appear to outweigh the positive CVS announcement.